Antimalarial and cytotoxic activities of roots and fruits fractions of *Astrodaucus persicus* extract

Saied Goodarzi 1, Mehdi Nateghpour 2, Parina Asgharian 3, Abbas Hadjiakhoondi 1, 4, Narguess Yassa 1, 4, Saeed Tavakoli 4, Jalal Mirzaei 4, Leila Farivar 2, Afsaneh Motevalli Haghi 2, Zahra Tofighi 1, 4*

1 Department of Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Pharmacognosy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

**ARTICLE INFO**

| Article type: | Original article |
|--------------|------------------|
| Article history: | Received: Jul 23, 2017 | Accepted: Sep 28, 2017 |
| Keywords: | Astrodaucus persicus, Apiaceae, Antimalaria, Cytotoxic, MTT assay, Plasmodium berghei |

**ABSTRACT**

Objective(s): *Astrodaucus persicus* (Apiaceae) is one of the two species of this genus which grows in different parts of Iran. Roots of this plant were rich in benzodioxoles and used as food additive or salad in Iran and near countries. The aim of present study was evaluation of antimalarial and cytotoxic effects of different fractions of *A. persicus* fruits and roots extracts.

Materials and Methods: Ripe fruits and roots of *A. persicus* were extracted and fractionated by hexane, chloroform, ethyl acetate and methanol, separately. Antimalarial activities of fractions were performed based on *Plasmodium berghei* suppressive test in mice model and percentage of parasitemia and suppression were determined for each sample. Cytotoxicity of fruits and roots fractions were investigated against human breast adenocarcinoma (MCF-7), colorectal carcinoma (SW480) and normal (L929) cell lines by MTT assay and IC_{50} of them were measured.

Results: Hexane fraction of roots extract (RHE) and ethyl acetate fraction of fruits extract (FEA) of *A. persicus* demonstrated highest parasite inhibition (73.3 and 72.3%, respectively at 500 mg/kg/day) which were significantly different from negative control group (*P*<0.05). In addition, RHE showed potent antitumor activities against MCF-7 (IC_{50} of 0.01 µg/ml), SW480 (IC_{50} of 0.36 µg/ml) and L929 (IC_{50} of 0.70 µg/ml) cell lines.

Conclusion: According to the results, RHE and FEA fractions of *A. persicus* could be introduced as excellent choice for antimalarial drug discovery. In addition, cytotoxic activity of RHE was noticeable.

**Introduction**

Malaria is one of the most important infectious diseases globally and the major health challenges in malaria risk areas. According to WHO malaria report, there were an estimated 212 million new cases of malaria and 429000 deaths in 2015 alone worldwide. The heaviest malaria burden belongs to African region countries. Iran showed more than 40% decrease in malaria incidence and mortality rates between 2010-2015 (1).

The greatest challenges against malaria control is resistance of mosquitoes to insecticides and parasites to antimalarial drugs. From four species of malaria parasites which naturally infect humans, *Plasmodium falciparum* has developed resistance to nearly all mainstay antimalarial drugs and *P. vivax* showed resistance to chloroquine derivatives (2-4).

Considerable costs of drugs and logistical problems especially in poor malaria endemic areas were other challenges for control of disease (5).

Over the previous 30 years, natural products are the sources of approximately two thirds of all drugs introduced (6). Medicinal plants are potential sources of novel, effective and affordable antiplasmodial compounds which can elucidate chemically or can constitute lead molecules for discovery of new antimalarial drugs (7, 8). Quinine present in *Cinchona* species, artemisinin from *Artemisia annua*, quassinoids in Simaroubaceae and limonoids in Meliaceae families were natural products with considerable antimalarial activities (9, 10). The *Astrodaucus* genus from Apiaceae family is native to Iran, Iraq, Syria, Turkey and Ukraine (11).

---

*Corresponding author: Zahra Tofighi. Department of Pharmacognosy and Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-21-64121220; Fax: +98-21-89771428; email: ztofighi@tums.ac.ir*
Two species of *A. persicus* (Boiss.) Drude and *A. orientalis* (L) Drude distributed in various parts of Iran.

Aerial parts and roots of *Astrodaucus* used as food additive or salad in some regions of Iran and Turkey (12). New compounds with 1,3-benzodioxole structures were isolated and elucidated from different fractions of *A. persicus* roots extract (13). Benzodioxoles demonstrated antimalarial, antioxidant, antitumor, antibacterial, antifungal, antiparasitic, pesticides and herbicides properties (14).

There was no investigation on antimalarial activities of *A. persicus*, therefore to fill this gap in, the present study was designed to evaluate antimalarial and cytotoxic activities of different fractions of fruits and roots extracts of *A. persicus*.

### Materials and Methods

**Plant materials**

Ripe fruits and roots of *A. persicus* (Boiss.) Drude were collected in September 2015 from Zanjan Province, Iran. Plant was deposited in Herbarium of Faculty of Pharmacy, Tehran University of Medical Sciences (6553-TEH; identified by Dr Y Ajani). The samples were dried in shade and powdered separately.

**Extraction and fractionation**

The *A. persicus* fruits (150 g) and roots (1190 g) were extracted separately with 80% methanol by maceration at 25±2 °C to obtain crude fruits extract (FE 17 g) and roots extract (RE 42.5 g). FE and RE were fractionated with hexane (FHE 2.88 g, RHE 15.63 g), chloroform (FCL 0.76 g, RCL 7.44 g), ethyl acetate (FEA 0.33 g, REA 2.54 g) and the residue named methanol fraction (FME 11.53 g, RME 15.25 g).

**Animals**

The Swiss albino male mice (20-25 g) were obtained from the Pasteur Institute of Iran. The animals were housed in comfortable cages at room temperature under 12 hr light-dark cycles with free access to standard pellet diet and clean water *ad libitum*. The study performed according to the Helsinki rules in animal house of School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. All procedures performed in studies involving animals were in accordance with the Ethical Standards of Tehran University of Medical Sciences (IR.TUMS.REC. 1394.935).

**Parasites**

Chloroquine-sensitive *Plasmodium berghei* (NIDC strain) was obtained from Haffkine Institute, India for induction of malaria in experimental mice.

Two weeks previous to the tests, mice were infected with 0.2 ml suspension of *P. berghei* via intra-peritoneal (IP) route and were used as donor.

**Inoculum preparation**

The parasitemia of the *P. berghei*-infected donor mice were measured every day. Four days after infection, parasitemia reached about 10%. The heart blood of infected donor mice was collected via cardiac puncture into heparinized test tube after anaesthetizing animals with ketamine/xylazine.

The blood was diluted with physiological saline. The dilution was done based on the parasitemia percentage of donor mice and RBC count of normal mice (15). Mice were then infected by injecting 0.2 ml of diluted blood suspension intraperitoneally (IP) which contained 10⁶ parasitized erythrocytes on day 0 (D0).

**Antimalarial test**

*Plasmodium berghei* suppressive test, a preclinical test for measurement of potential bioactivity of new compounds and extracts, was conducted for determination of the drug doses for producing 50% suppression of parasitemia (16). Mice were grouped into eleven groups of five individual. Treatment was started two hrs after injection of parasites and then continued once daily for 21 days. Group I to IV and V to VIII were treated with 500 mg/kg/day (IP) of hexane, chloroform, ethyl acetate and methanol fractions of fruits and roots extracts, respectively. Positive and negative control groups received chloroquine (10 mg/kg/day) and normal saline as vehicle (0.2 ml/kg/day), respectively. Group XI (blank) was infected mice which didn’t receive anything. On the 4th day (D4), 7th day (D7), 14th day (D14), 21st day (D21), thin blood smears were prepared from the tail of each mouse on microscopic slides, then they were fixed with methanol and stained with 10% Giemsa in distilled water. The numbers of parasitized erythrocytes were counted and percentage of parasitemia and inhibition were determined for each sample. Parasitemia percent and suppression percent were calculated by following formula, respectively (17, 18).

\[
\text{%Parasitemia} = \frac{\text{Number of Infected RBCs}}{\text{Total Number of RBCs}} \times 100
\]

\[
\text{%suppression} = (\%\text{Parasitemia of BG} - \%\text{Parasitemia of TG}) / \%\text{Parasitemia of BG} \times 100
\]

Where BG means blank group and TG means treated group. Thin smears of treated mice were investigated on days 7, 14 and 21 after infection, too. Results were expressed as mean±SD. One way analysis of variance (ANOVA) and Tukey post hoc were used for analyzing the data and *P*< 0.05 was considered significant.

**Cytotoxicity evaluation**

**Chemicals**

- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich, USA); RPMI 1640, fetal bovine serum (FBS), penicillin streptomycin (GIBCO™ Invitrogen, USA) and trypsin-EDTA (Boehringer; Germany) were prepared.
Antimalarial and cytotoxic effects of A. persicus cell extracts

**Table 1. Antimalarial effect of different fractions of Astrodaucus persicus roots and fruits extracts against Plasmodium berghei infection in mice**

| Treatment | Doses | 4th Day | 7th Day | 14th Day | 21st Day |
|-----------|-------|---------|---------|----------|---------|
| Normal saline | 0.2 ml/kg | 7.70±4.13 (13.3) | 19.00±6.63 (26.7) | 25.60±4.72 (16.3) | 50.50±1.32 (0.0) |
| RHE | 500 mg/kg | 1.60±1.14 (73.3)* | 6.80±1.56 (64.2) | 26.00±1.69 (15.4) | 46.75±2.47 (9.2)* |
| RCL | 500 mg/kg | 3.70±2.49 (38.3) | 8.10±1.71 (57.4) | 29.87±2.21 (2.8)* | 48.00±2.12 (6.8)* |
| REA | 500 mg/kg | 4.10±1.78 (31.7) | 10.10±3.58 (46.8) | 29.83±3.21 (3.0) | ---- |
| RME | 500 mg/kg | 4.25±2.96 (29.2) | 11.50±8.06 (31.2) | 20.37±1.36 (33.7) | 48.00±3.94 (8.4)* |
| FHE | 500 mg/kg | 4.08±0.86 (35.3) | 17.66±4.40 (39.1) | 19.80±4.45 (35.2) | 47.33±1.53 (6.3) |
| FCL | 500 mg/kg | 4.70±1.44 (25.5) | 18.6±2.36 (35.7) | 23.00±1.41 (24.0) | 37.00±0.0 (26.7)* |
| FEA | 500 mg/kg | 1.75±1.71 (72.3) | 14.25±9.63 (50.9) | 14.75±8.94 (51.7) | 39.33±9.82 (22.1)* |
| FME | 500 mg/kg | 3.1±0.60 (50.3) | 20.57±4.72 (29.1) | 24.08±5.37 (21.2) | ---- |
| Chloroquine | 10 mg/kg | 0.00±0.00 (100) | 0.00±0.00 (100) | 0.00±0.00 (100) | 0.00±0.00 (100) |

Values are expressed as mean±SD. RHE: Root hexane fraction, RCL: root chloroform fraction, REA: Root ethyl acetate fraction, RME: Root methanol fraction, FHE: Fruit hexane fraction, FCL: Fruit chloroform fraction, FEA: Fruit ethyl acetate fraction, FME: Fruit methanol fraction.

*: There was significant difference with normal saline (P<0.05). The superscript number means the number of died from five mice in each group.

**Table 2. Cytotoxicity of different fractions of Astrodaucus persicus roots and fruits extracts by MTT assay**

| Samples | IC50 (µg/ml) | MCF7 | SW480 | L929 |
|---------|--------------|------|-------|------|
| RHE | 0.01±0.0170(70) | 0.36±0.119(1.9) | 0.70±0.12 |
| RCL | 42±2.0.48(2.4) | 71.4±0.17(1.4) | 100.0±0.93 |
| REA | 250.27±0.15>4.0 | 397.93±0.12>25.0 | >1000 |
| RME | >1000 | >1000 | >1000 |
| FHE | >1000 | >1000 | >1000 |
| FCL | >1000 | 5.42±1.24>184.5 | >1000 |
| FEA | >1000 | >1000 | >1000 |
| FME | >1000 | >1000 | >1000 |
| Dexamethasone | 0.35±0.071(6.5) | 2.50±0.80(2.4) | 0.55±0.06(0.2) |

Results are expressed as IC50 values (µg/ml), means±SD of three determinations; SI: selectivity index, MCF7: breast adenocarcinoma, SW480: colorectal carcinoma and L929: normal cell lines, RHE: Root hexane fraction, RCL: Root chloroform fraction, REA: Root ethyl acetate fraction, RME: Root methanol fraction, FHE: Fruit hexane fraction, FCL: Fruit chloroform fraction, FEA: Fruit ethyl acetate fraction, FME: Fruit methanol fraction.

**Cell culture**

The human breast adenocarcinoma (MCF-7), colorectal carcinoma (SW480) and normal (L929) cell lines were cultured in RPMI 1640 cell culture medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. All cell lines were maintained in a humidified incubator with an atmosphere of 95% air and 5% CO2 at 37°C.

**MTT assay**

Cell viability was determined by the microculture tetrazolium/formazan assay using MTT (19). MTT (5 mg/ml) was dissolved in PBS. The solution was filtered through a 0.2 µm filter and stored at 2-8°C. Cells were cultured in 96-well plates at density of 10⁴ cells/well in 100 µl medium at 37°C for 24 h. Following incubation, the medium of each well was replaced by 100 µl fresh medium containing various concentrations of different fractions of roots and fruits of A. persicus extract, which were freshly prepared in DMSO. The final concentration of DMSO was adjusted lower than 1% of total volume. After 48 hr incubation, the medium removed and 20 µl of MTT reagent was added to cells. The plates were incubated at 37°C for 4 hr in a humidified 5% CO2 atmosphere. Then the MTT was removed and pure DMSO (100 µl/well) was added to lyse the cells and dissolve formazane crystals. The purple formazane salts formed from enzymatic reduction of yellowish MTT in mitochondria of viable cells. The absorbance was measured immediately using a micro plate reader (Anthos, Austria) at 570 nm. The cell survival was calculated by the following formula:

% Cell survival = Mean absorbance in test wells/Mean absorbance in control wells x 100

The results were generated from three independent experiments; each experiment was performed in triplicate. The IC50 (the median growth inhibitory concentration) was calculated from a dose response curve plotted in the Sigma Plot 10 software.

The selectivity index (SI) of fractions was measured according to the following equation:

SI= IC50 of none cancer cells / IC50 of cancer cells (20).
Results

Antimalarial activity
Chemo suppressive activity of different fractions of the roots and fruits of A. persicus extract against P. berghei infection in mice demonstrated in Table 1.

RHE and FEA were the most active fractions exhibiting 73.3 and 72.3 % suppression of P. berghei parasitemia on the fourth day, respectively. RHE, RCL and FEA were fractions with highest parasite inhibition (64.2, 57.4 and 50.9, respectively) on the seventh day. Statistical analysis demonstrated only RHE and FEA were significantly different from negative control group on the fourth day (P=0.045 and 0.023, respectively). RHE, RCL and FEA didn’t show any significant difference from control on the seventh day (P=0.19, 0.43 and 0.78, respectively).

Cytotoxicity assay
Cytotoxicity of different fractions of fruits and roots of A. persicus extract were evaluated on the human breast adenocarcinoma (MCF-7), colorectal carcinoma (SW480) and normal (L929) cell lines by MTT assay and IC₅₀ were demonstrated in Table 2. RHE and RCL fractions exhibited potent cytotoxic effects on MCF-7, SW480 and L929 cell lines, while REA fraction showed cytotoxicity on MCF-7 and SW480 cell lines in high doses (IC₅₀ equal to 250.27 and 397.93 µg/ml, respectively). REM fraction showed no cytotoxic effects on different cell lines. From different fractions of fruits extract, only FCL showed potent cytotoxicity (IC₅₀ up to 5.42 µg/ml) on SW480 cell line and other fractions didn’t show any toxicity.

Discussion
Medicinal plants contain a great variety of metabolites with different structures and biological activities therefore they can be good choices for drug discovery including antimalarial drugs. Two antimalarial drugs of quinine and artemisinin, currently in use have been elucidated from Cinchona species and Artemisia annua traditionally used for malaria treatment.

In present study, antimalarial activity of different fractions of fruits and roots extracts of A. persicus against P. berghei infection were investigated in mice and cytotoxicity of them against cancer and normal cell lines were reported.

The parasitemia suppression percentage of almost all roots and fruits fractions of A. persicus extract were upper than 30% on fourth and seventh days. The previous investigations demonstrated when parasitemia suppression percentage were more than 30%, the compound or extract is considered as active (21, 22). Another researchers categorized in vivo antimalarial activity of plants extracts as moderate, good or very good when the extracts at 500, 250 and 100 mg/kg/day showed 50% or more chemosuppression, respectively (23). According to this classification, only FEA and RHE fractions with parasitemia inhibition extra 50% at 500 mg/kg were effective against malaria.

Intercalation in DNA, inhibition of protein synthesis, prevention of parasite invasion to new RBCs (24, 25), reducing parasite nutrient intake (26), antioxidant and free radical scavenging activity (17) and immunomodulatory effects (27) were proposed as mechanisms for action of antiplasmodial drugs. According to previous investigation, roots extract of A. persicus demonstrated potent antioxidant effects and high amounts of total phenolic compounds (12). Also there were reports about dose and time dependent antiproliferative and cytotoxic effects of both roots and aerial parts of A. persicus extracts (28, 29). In conclusion, both antioxidant activity and cytotoxicity could be considered as antiplasmodial mechanisms of roots extract of A. persicus.

Many antimalarial molecules which discovered have high toxicity and low therapeutic indices (30). Therefore cytotoxicity of different fractions of roots and fruits of A. persicus were evaluated.

Following the standard of Plant Screening Program of US National Cancer Institute (NCI), possessing an IC₅₀ less than 20 µg/ml for crude extracts and less than 4 µg/ml for pure compounds are considered active against the tested cancer cells (19). Based on these criteria, only RHE fraction of A. persicus extract demonstrated potent anticancer activities against MCF-7 (IC₅₀ of 0.01 µg/ml), SW480 (IC₅₀ of 0.36 µg/ml) and L929 (IC₅₀ of 0.70 µg/ml). This fraction showed potent activity against breast and colorectal cancer cell lines in comparison to doxorubicin with IC₅₀ of 0.35 and 2.50 µg/ml, respectively. Cytotoxic activity of RHE on normal cell lines was almost equal to doxorubicin (IC₅₀ of 0.55 µg/ml). Another investigation showed IC₅₀ of cisplatin against MCF-7 was equal to 19.28 µg/ml and against SW480 was equal to 25.69 µg/ml (31). It was obvious that RHE fraction of A. persicus was more potent than doxorubicin as an anticancer drug. On the other side, the selectivity of RHE fraction for breast adenocarcinoma was 70 times more than normal cell line and for colorectal carcinoma was almost 2 times more than normal cell line. The previous studies demonstrated compounds with selectivity index higher than 10 was considered as selective while those with SIs lower than 10 but higher than 1 were belong to non-selective ones (20). The results demonstrated RHE could be an excellent choice for anticancer drug discovery especially for its selective effects on breast cancer. FCL fraction showed potent selectivity against colorectal carcinoma cell lines but IC₅₀ of this fraction was lower than doxorubicin. It could be considered for elucidation of its compounds as leads for anticancer drugs.

Bioactive secondary metabolites containing benzodioxole structures were responsible for many pharmacological activities of plants. Lycorine, a natural alkaloid containing benzodioxole structure, isolated from Amaryllidaceae genera, was active against...
chloroquine-sensitive strains of *P. falciparum* (32). Other benzodioxole compounds like safrrole, apiole and myristicin showed carcinogenic and other toxicological effects (33-35). Clinical tumor agents like etoposide, teniposide and podophyllotoxin have methylenediocy unit in their structures (36, 37). Previous studies showed excellent bioavailability and low cytotoxicity of a variety of anticancer drugs with benzodioxole structures (38). Low cytotoxicity of molecules with benzodioxole structures converted them to considerable antimalarial compounds. Elucidation of active antitumoral compounds from effective fractions (RHE and FEA) of *A. persicus* extract and investigation of their toxicity were proposed for further studies.

**Conclusion**

The results of this study have shown potent antimalarial and cytotoxic effects of hexane fraction of *A. persicus* roots extract. On the other hand, ethyl acetate fraction of fruits showed antimalarial activity with no cytotoxicity. The existence of bioactive compound(s) in RHE and FEA fractions or the synergist effects of compounds may be the reason of such good results.

**Acknowledgment**

This research was a Pharm D thesis which was supported by a grant of Tehran University of Medical Sciences and Health Services (No 29070).

**References**

1. World Health Organization (WHO). World Malaria Report 2016. Switzerland: 2017.
2. Mengiste B, Makonnen E, Urge K. *In vivo* antimalarial activity of *Dodonaea angustifolia* seed extracts against *Plasmodium berghei* in mice model. Momona Ethiop J Sci 2012; 4:47-63.
3. Khodadadi M, Nateghpour M, Souri E, Farivar L, Motevali Haghi A, et al. Evaluation of effectiveness of ethanolic extract of *Artemisia aurchi*, individually and in combination with chloroquine, on chloroquine-sensitive strain of *Plasmodium berghei* in sourian mice. Iranian J Pub Health 2013; 42: 883-888.
4. Muluye AB, Melese E, Adinew GM. Antimalarial activity of 80% methanolic extract of *Brassica nigra* (L) Koch. (Brassicaceae) seeds against *Plasmodium berghei* infection in mice. BMC Complement Altern Med 2015; 15:367-375.
5. Langhorne J, Ndungu FM, Sponsa AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9:725-732.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75:311-335.
7. Onguene PA, Ntie-Kang F, Lifongo LL, Ndom JC, Sippel W, Mbaze LM. The potential of antimalarial compounds derived from African medicinal plants. Part I: A pharmacological evaluation of alkaloids and terpenoids. Malar J 2013; 12:449-474.
8. Pandey A, Tripathi S. Concept of standardization, extraction and pre-phytocchemical screening strategies for herbal drug. J Pharmacogn Phytochem 2014; 2:115-119.
9. Schmidt TJ, Khalid SA, Romanha AJ, Alves TMA, Biavatti MW, Brun R, et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases—part I. Curr Med Chem 2012; 19:2128-2175.
10. Schmidt TJ, Khalid SA, Romanha AJ, Alves TMA, Biavatti MW, Brun R, et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases—part II. Curr Med Chem 2012; 19:2176-2228.
11. Nazemiyeh H, Razavi SM, Delazar A, Aenaashiri S, Knot NS, Daniali S, et al. Distribution profile of volatile constituents in different parts of *Astrodaucus orientalis* (L) Drude. Rec Nat Prod 2009; 3:126-130.
12. Goodarzi S, Hadjiakhoondi A, Yassa N, Khanavi M, Tofighi Z. Essential oils chemical composition, antioxidant activities and total phenols of *Astrodaucus persicus*. Iran J Basic Med Sci 2016; 19:159-165.
13. Goodarzi S, Hadjiakhoondi A, Yassa N, Khanavi M, Tofighi Z. New benzodioxole compounds from the root extract of *Astrodaucus persicus* Iran J Pharm Res 2016; 15: 901-906.
14. Gupta SD, Rao GB, Bommaka MK, Raghavendra NM, Aketi S. Eco-sustainable synthesis and biological evaluation of 2-phenyl 1,3-benzodioxole derivatives as anticancer, DNA binding and antibacterial agents. Arab J Chem 2016; 9:5875-1883.
15. Nateghpour M, Farivar L, Souri E, Hajjaran H, Mohababi M, Motevali Haghi A. The effect of *Oroxylon persica* in combination with chloroquine on chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium berghei* using *in-vivo* fixed ratios method. Iran J Pharm Res 2012; 11:583-588.
16. Peters W. Chemotherapy and drug resistance in malaria. London: Academic Press; 1970: P.876.
17. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3:509-520.
18. Kalra BS, Chawla S, Gupta P, Valerie N. Screening of antimalarial drugs: An overview. Indian J Pharmacol 2006; 38:5-12.
19. Tofighi Z, Asgharian P, Goodarzi S, Hadjiakhoondi A, Ostad SN, Yassa N. Potent cytotoxic flavonoids from Iranian *Securigera seuridaca*. Med Res Chem 2014; 23: 1718-1724.
20. Pena-Moran OA, Villareal ML, Alvarez-Berber L, Meneses-Acosta A, Rodriguez-Lopez V. Cytotoxicity, post-treatment recovery, and selectivity analysis of naturally occurring podophyllotoxins from *Bursera fagaroides var. fagaroides* on breast cancer cell lines. Molecules 2016; 21: 1013-1028.
21. Krettli AU, Adelabo JO, Krettli LG. Testing of natural products and synthetic molecules aiming at new antimalarials. Curr Drug Targets 2009; 10:261-270.
22. Adugna M, Feyera T, Taddess W, Admasu P. *In vivo* antimalarial activity of crude extract of aerial part of *Artemisia abyssinica* against *Plasmodium berghei* in mice. Global J Pharmacol 2014; 8:460-468.
23. Dehavo E, Bourdy G, Quevauv, Cunoz N, Ruiz G, Sauvain M. A search for natural bioactive compounds in Bolivia through a multidisciplinary approach. Part V. Evaluation of the antimalarial activity of plants used by the Tacona Indians. J Ethnopharmacol 2001; 77:91-98.
24. Rasanoaive P, Wright CW, Wilcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J 2011; 10:4-15.
25. Builders MJ, Uguju MO, Aguiyi C. Antimalarial potential of the African mistletoe: *Agelanthus dodoneifolius* Polh & Wiens. Indian J Pharm Sci 2012; 74:223-229.
26. Al-Adhroey AH, Nor ZM, Al-Meldiiahi HM, Mahmud R. Median lethal dose, antimalarial activity, phytocchemical screening and radical scavenging of methanolic langs galangal *Himzone* extract. Molecules 2010; 15:8366-8376.
27. Ajaiyeoba E, Falade M, Ogbole O, Olpalo L, Akohoye D. In vivo antimalarial and cytotoxic properties of *Annona senegalensis* extract. Afr J Trad CAM 2006; 3:137-141.
28. Abdolmohammadi MH, Fouladdel Sh, Shafiee A, Amin Gh, Ghaffari SM, Azizi E. Anticancer effects and cell cycle analysis on human breast cancer T47D cells treated with extracts of *Astrodaucus persicus* (Boiss.) Drude in comparison to doxorubicin. DARU 2008; 16:112-118.
29. Azizi E, Abdolmohammadi MH, Fouladdel Sh, Shafiee A, Amin Gh, Ghaffari SM. Evaluation of p53 and Bcl-2 genes and proteins expression in human breast cancer T47D cells treated with extracts of *Astrodaucus persicus* (Boiss.) Drude in comparison to tamoxifen, immunocytochemistry. DARU 2009; 17:181-186.
30. Sullivan JDJ, Kaludov N, Martinov MN. Discovery of potent, novel, non-toxic antimalarial compounds via quantum modelling, virtual screening and *in vitro* experimental validation. Malar J 2011; 10:274-182.
31. Fu YH, Li SL, Li SF, He HP, Di YT, Zhang Y, Hao XJ. Cytotoxic eburnamine-aspidospermine type bisindole alkaloids from *Bousigonia mekongensis*. Fitoterapia 2014; 98:45-52.
32. Cedron JC, Gutierrez D, Flores N, Ravelo AG, Estevez-Braun A. Synthesis and antiplasmodial activity of lycorine derivatives. Bioorganic Med Chem 2010; 18:4694-4701.
33. Miller EC, Swanson AB, Phillips DH, Fletcher TL, Liem A, Miller JA. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res 1983; 43:1124-1134.
34. Leite ACL, Silva KP, Souza IA, Araujo JM, Brondani DJ. Synthesis, antitumor and antimicrobial activities of new peptidyl derivatives containing the 1,3-benzodioxole system. Eur J Med Chem 2004; 39:1059-1065.
35. Hsu-Man L, Po-Tsun K, Chao-Lu H, Jung-Yie K, Ho L, Ding-Yah Y, et al. Study of the anti-proliferative activity of 5-substituted 4,7-dimethoxy-1,3-benzodioxole derivatives of SY-1 from *Antrodia camphorata* on human COLO 205 colon cancer cells. J Evol Based Complement Altern Med 2011; 1-8.
36. Capilla AS, Sanchez I, Caignard DH, Renard P, Pujol MD. Antitumor agents, Synthesis and biological evaluation of new compounds related to podophyllotoxin, containing the 2, 3-dihydro-1,4-benzodioxin system. Eur J Med Chem 2001; 36:389-393.
37. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey K, Liu L. Non intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259:13560-13566.
38. Hai-Hong W, Ke-Ming Q, Hong-En C, Yu-Shun Y, Yin L, Man X, et al. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents. Bioorg Med Chem Lett 2013; 21:448-455.